Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2018

Open Access 01-12-2018 | Study protocol

Use of monomeric and oligomeric flavanols in the dietary management of patients with type 2 diabetes mellitus and microalbuminuria (FLAVA trial): study protocol for a randomized controlled trial

Authors: Mardin Rashid, Adrie J. M. Verhoeven, Monique T. Mulder, Reinier Timman, Yvonne van Beek-Nieuwland, Athumani A. Athumani, Adrienne A. M. Zandbergen, Hans E. van der Wiel, Eric J. G. Sijbrands, Kirsten A. Berk

Published in: Trials | Issue 1/2018

Login to get access

Abstract

Background

Patients with type 2 diabetes mellitus (T2D) are prone to micro- and macro-vascular complications. Monomeric and oligomeric flavanols (MOF) isolated from grape seeds (Vitis vinifera) have been linked to improved endothelial function and vascular health. The aim of this study is to determine the effect of a daily supplementation of 200 mg MOF on renal endothelial function of patients with T2D and microalbuminuria.

Methods/design

For this double-blind, placebo-controlled, randomized, multicenter trial 96 individuals (ages 40–85 years) with T2D and microalbuminuria will be recruited. Participants will be randomly assigned to the intervention group, receiving 200 mg of MOF daily for 3 months, or to the control group, receiving a placebo. The primary endpoint is the evolution over time in albumin excretion rate (AER) until 3 months of intervention as compared with placebo. Secondary endpoints are the evolution over time in established plasma markers of renal endothelial function—asymmetric dimethylarginine (ADMA), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular cell adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), and von Willebrand Factor (vWF)—until 3 months of intervention as compared with placebo. Mixed modeling will be applied for the statistical analysis of the data.

Discussion

We hypothesize that T2D patients with microalbuminuria have a medically determined requirement for MOF and that fulfilling this requirement will result in a decrease in AER and related endothelial biomarkers. If confirmed, this may lead to new insights in the dietary management of patients with T2D.

Trial registration

Nederlands Trial Register, NTR4669, registered on 7 July 2014.
Appendix
Available only for authorised users
Literature
1.
IDF Diabetes Atlas. 8th edn: International Diabetes Federation; 2017. Available from: http://​www.​diabetesatlas.​org.​ Accessed 2 Feb 2018.
2.
Lee ET, Keen H, Bennett PH, Fuller JH, Lu M. Follow-up of the WHO multinational study of vascular disease in diabetes: general description and morbidity. Diabetologia. 2001;44(Suppl 2):S3–13.CrossRefPubMed
3.
Turner RC, Holman RR. Lessons from UK prospective diabetes study. Diabetes Res Clin Pract. 1995;28(Suppl):S151–7.CrossRefPubMed
4.
Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8:18.CrossRefPubMedPubMedCentral
5.
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003;63(1):225–32.CrossRefPubMed
6.
Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis. 2011;218(1):13–8.CrossRefPubMed
7.
Hellemons ME, Kerschbaum J, Bakker SJ, Neuwirt H, Mayer B, Mayer G, et al. Validity of biomarkers predicting onset or progression of nephropathy in patients with type 2 diabetes: a systematic review. Diabet Med. 2012;29(5):567–77.CrossRefPubMed
8.
Blomster JI, Zoungas S, Chalmers J, Li Q, Chow CK, Woodward M, et al. The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes mellitus. Diabetes Care. 2014;37(5):1353–9.CrossRefPubMed
9.
Rasmussen SE, Frederiksen H, Struntze Krogholm K, Poulsen L. Dietary proanthocyanidins: occurrence, dietary intake, bioavailability, and protection against cardiovascular disease. Mol Nutr Food Res. 2005;49(2):159–74.CrossRefPubMed
10.
Schwitters B. Dr. Masquelier’s mark on health. Nieuwegein: Hentenaar-Boek; 2004.
11.
European FSA. Scientific opinion on the substantiation of a health claim related to cocoa flavanols and maintenance of normal endothelium-dependent vasodilation pursuant to article 13(5) of regulation (EC) no 1924/20061. Eur Food Safety Authority. 2012;10(7):2809–21.
12.
Vogiatzoglou A, Mulligan AA, Luben RN, Lentjes MA, Heiss C, Kelm M, et al. Assessment of the dietary intake of total flavan-3-ols, monomeric flavan-3-ols, proanthocyanidins and theaflavins in the European Union. Br J Nutr. 2014;111(8):1463–73.CrossRefPubMed
13.
Zamora-Ros R, Forouhi NG, Sharp SJ, Gonzalez CA, Buijsse B, Guevara M, et al. Dietary intakes of individual flavanols and flavonols are inversely associated with incident type 2 diabetes in European populations. J Nutr. 2014;144(3):335–43.CrossRefPubMed
14.
Tresserra-Rimbau A, Rimm EB, Medina-Remon A, Martinez-Gonzalez MA, de la Torre R, Corella D, et al. Inverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study. Nutr Metab Cardiovasc Dis. 2014;24(6):639–47.CrossRefPubMed
15.
Jennings A, Welch AA, Spector T, Macgregor A, Cassidy A. Intakes of anthocyanins and flavones are associated with biomarkers of insulin resistance and inflammation in women. J Nutr. 2014;144(2):202–8.CrossRefPubMed
16.
Kar P, Laight D, Rooprai HK, Shaw KM, Cummings M. Effects of grape seed extract in type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity. Diabet Med. 2009;26(5):526–31.CrossRefPubMed
17.
Fromatin M. Les oligomeres procyanidoliques dans le traitement de la fragilite capillaire et de la retinopathie chez les diabetiques. Med Int. 1981;16(11):432–4.
18.
Largue G, Olivier-Martin F, Grillot A. Etude des effets des oligomers de procyanidol sur la resisrance capillaire dans l’hypertension arterielle et certaines nephropathies. Sem Hop Paris. 1981;57(33–36):1399–401.
19.
Weseler AR, Ruijters EJ, Drittij-Reijnders MJ, Reesink KD, Haenen GR, Bast A. Pleiotropic benefit of monomeric and oligomeric flavanols on vascular health--a randomized controlled clinical pilot study. PLoS One. 2011;6(12):e28460.CrossRefPubMedPubMedCentral
20.
Milenkovic D, Vanden Berghe W, Boby C, Leroux C, Declerck K, Szarc Vel Szic K, et al. Dietary Flavanols modulate the transcription of genes associated with cardiovascular pathology without changes in their DNA methylation state. PLoS One. 2014;9(4):e95527.CrossRefPubMedPubMedCentral
21.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.CrossRefPubMed
22.
American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–27.CrossRef
23.
24.
Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol. 2005;61(7):483–90.CrossRefPubMed
25.
Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995;99(5):497–504.CrossRefPubMed
26.
Aberson CL. Applied power analysis for the behavioral sciences. New York: Routledge/Taylor & Francis Group; 2010. p. xiv. 257 US
27.
Sun B, Ricardo da Silva J, Spranger I. Critical factors of vanillin assay for catechins and proanthocyanidins. J Agric Food Chem. 1998;46:4267–74.CrossRef
28.
Freedman JE, Parker C 3rd, Li L, Perlman JA, Frei B, Ivanov V, et al. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation. 2001;103(23):2792–8.CrossRefPubMed
29.
Singer J, Willett JB. Applied longitudinal data analysis - modeling change and event occurrence. Oxford: Oxford University Press; 2003.CrossRef
30.
Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2000.
31.
Naidoo DP. The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. Cardiovasc J S Afr. 2002;13(4):194–9.PubMed
32.
Ochodnicky P, Henning RH, van Dokkum RP, de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol. 2006;47(Suppl 2):S151–62. discussion S72–6CrossRefPubMed
33.
Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Heerspink HJ, van Raalte DH. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. 2015; p. 2213–8595. (Electronic)
34.
Feringa HH, Laskey DA, Dickson JE, Coleman CI. The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. J Am Diet Assoc. 2011;111(8):1173–81.CrossRefPubMed
Metadata
Title
Use of monomeric and oligomeric flavanols in the dietary management of patients with type 2 diabetes mellitus and microalbuminuria (FLAVA trial): study protocol for a randomized controlled trial
Authors
Mardin Rashid
Adrie J. M. Verhoeven
Monique T. Mulder
Reinier Timman
Yvonne van Beek-Nieuwland
Athumani A. Athumani
Adrienne A. M. Zandbergen
Hans E. van der Wiel
Eric J. G. Sijbrands
Kirsten A. Berk
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Trials / Issue 1/2018
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-018-2762-9

Other articles of this Issue 1/2018

Trials 1/2018 Go to the issue

Study protocol

Impact of collaborative pharmaceutical care on in-patients’ medication safety: study protocol for a stepped wedge cluster randomized trial (MEDREV study)

Study protocol

Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial

Study protocol

A dose-response study of aerobic training for oxygen uptake, oxidative stress and cardiac autonomic function in type 2 diabetes mellitus: study protocol for a randomized controlled trial

Study protocol

SENSory re-learning of the UPPer limb after stroke (SENSUPP): study protocol for a pilot randomized controlled trial

Study protocol

Improving eye care in residential aged care facilities using the Residential Ocular Care (ROC) model: study protocol for a multicentered, prospective, customized, and cluster randomized controlled trial in Australia

Study protocol

Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial